Follow
Sandro Pignata
Sandro Pignata
Istituto tumori di Napoli Pascale
Verified email at istitutotumori.na.it
Title
Cited by
Cited by
Year
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised …
E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ...
The lancet oncology 18 (9), 1274-1284, 2017
16382017
Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients
SA Curley, F Izzo, P Delrio, LM Ellis, J Granchi, P Vallone, F Fiore, ...
Annals of surgery 230 (1), 1, 1999
15721999
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ...
The Lancet 390 (10106), 1949-1961, 2017
15682017
Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
I Ray-Coquard, P Pautier, S Pignata, D Pérol, A González-Martín, ...
New England Journal of Medicine 381 (25), 2416-2428, 2019
14882019
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N Colombo, C Sessa, A Du Bois, J Ledermann, WG McCluggage, ...
Annals of Oncology 30 (5), 672-705, 2019
10272019
The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with …
D Cibula, R Pötter, F Planchamp, E Avall-Lundqvist, D Fischerova, ...
Virchows Archiv 472, 919-936, 2018
8962018
Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
E Pujade-Lauraine, U Wagner, E Aavall-Lundqvist, V Gebski, M Heywood, ...
Journal of clinical oncology 28 (20), 3323-3329, 2010
7022010
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
UA Matulonis, R Shapira-Frommer, AD Santin, AS Lisyanskaya, S Pignata, ...
Annals of Oncology 30 (7), 1080-1087, 2019
5422019
Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients
SA Curley, P Marra, K Beaty, LM Ellis, JN Vauthey, EK Abdalla, C Scaife, ...
Annals of surgery 239 (4), 450-458, 2004
4692004
Lenvatinib plus pembrolizumab for advanced endometrial cancer
V Makker, N Colombo, A Casado Herráez, AD Santin, E Colomba, ...
New England Journal of Medicine 386 (5), 437-448, 2022
4292022
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
S Pignata, G Scambia, D Katsaros, C Gallo, E Pujade-Lauraine, ...
The lancet oncology 15 (4), 396-405, 2014
4082014
Incorporation of pazopanib in maintenance therapy of ovarian cancer
A Du Bois, A Floquet, JW Kim, J Rau, JM Del Campo, M Friedlander, ...
Journal of clinical oncology 32 (30), 3374-3382, 2014
3792014
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer
G Ferrandina, M Ludovisi, D Lorusso, S Pignata, E Breda, A Savarese, ...
Journal of Clinical Oncology 26 (6), 890-896, 2008
3632008
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients
Cancer of the Liver Italian Program (CLIP) Investigators
Hepatology 28 (3), 751-755, 1998
2951998
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double …
A Poveda, A Floquet, JA Ledermann, R Asher, RT Penson, AM Oza, ...
The Lancet Oncology 22 (5), 620-631, 2021
2762021
Treatment of recurrent ovarian cancer
S Pignata, SC Cecere, A Du Bois, P Harter, F Heitz
Annals of Oncology 28, viii51-viii56, 2017
2612017
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial
S Pignata, G Scambia, G Ferrandina, A Savarese, R Sorio, E Breda, ...
Journal of clinical oncology 29 (27), 3628-3635, 2011
2612011
The forefront of ovarian cancer therapy: update on PARP inhibitors
MR Mirza, RL Coleman, A González-Martín, KN Moore, N Colombo, ...
Annals of Oncology 31 (9), 1148-1159, 2020
2422020
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
A Du Bois, G Kristensen, I Ray-Coquard, A Reuss, S Pignata, N Colombo, ...
The Lancet Oncology 17 (1), 78-89, 2016
2302016
Clinical trials in recurrent ovarian cancer
M Friedlander, E Trimble, A Tinker, D Alberts, E Avall-Lundqvist, M Brady, ...
International Journal of Gynecologic Cancer 21 (4), 2011
2282011
The system can't perform the operation now. Try again later.
Articles 1–20